{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=15",
    "query": {
      "condition": "AdverseEvent",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 927,
    "total_pages": 93,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T00:00:41.401Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02216357",
      "title": "Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aspirin Exacerbated Respiratory Disease (AERD)"
      ],
      "interventions": [
        {
          "name": "Ifetroban, Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2014-08",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Overland Park, Kansas • West Nyack, New York",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "West Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02216357"
    },
    {
      "nct_id": "NCT03857100",
      "title": "Improving Wisely - Polypharmacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adverse Drug Event"
      ],
      "interventions": [
        {
          "name": "Audit and feedback - letter and report",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 11000,
      "start_date": "2019-01-04",
      "completion_date": "2021-01-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03857100"
    },
    {
      "nct_id": "NCT00578136",
      "title": "Analgesic Efficacy After Umbilical Hernia Repair in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Umbilical Hernia"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 52,
      "start_date": "2006-11",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-08-15",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00578136"
    },
    {
      "nct_id": "NCT07278336",
      "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-901",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 285,
      "start_date": "2025-11-27",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07278336"
    },
    {
      "nct_id": "NCT04750226",
      "title": "Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease (PD)"
      ],
      "interventions": [
        {
          "name": "ABBV-951",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2021-02-18",
      "completion_date": "2026-04-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04750226"
    },
    {
      "nct_id": "NCT04682587",
      "title": "To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 481,
      "start_date": "2021-02-24",
      "completion_date": "2021-04-05",
      "has_results": true,
      "last_update_posted_date": "2025-01-03",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04682587"
    },
    {
      "nct_id": "NCT07838649",
      "title": "Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma Cancer",
        "Breast Cancer",
        "Cancer of the Breast",
        "Non-Hodgkin Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "68Ga-Galmydar",
          "type": "DRUG"
        },
        {
          "name": "PET/MRI",
          "type": "DEVICE"
        },
        {
          "name": "18F-FDG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "21 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2026-11-01",
      "completion_date": "2029-12-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07838649"
    },
    {
      "nct_id": "NCT07196644",
      "title": "A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors Harboring MET Amplification"
      ],
      "interventions": [
        {
          "name": "Telisotuzumab Adizutecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-12-01",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 18,
      "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07196644"
    },
    {
      "nct_id": "NCT01833234",
      "title": "Epilepsy Impact Scale",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Interviews and questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2012-07",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-04-13",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01833234"
    },
    {
      "nct_id": "NCT00747461",
      "title": "Interventional Cryotherapy for the Eradication of Benign Airway Disease (\"ICE the BAD\")",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lung Diseases, Obstructive",
        "Sarcoidosis",
        "Wegener's Granulomatosis",
        "Rhinoscleroma",
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "CryoSpray Ablation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CSA Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2008-10",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2015-08-18",
      "last_synced_at": "2026-10-23T00:00:41.401Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00747461"
    }
  ]
}